

REPORT DOCUMENTATION PAGE			<i>Form Approved</i> OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.				
1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE 5.Sep.02		3. REPORT TYPE AND DATES COVERED MAJOR REPORT
4. TITLE AND SUBTITLE ATHEROGENESIS 2002, NEW CONCEPTS IN PLAQUE VULNERABILITY AND C REACTIVE PROTEIN			5. FUNDING NUMBERS	
6. AUTHOR(S) MAJ DE JONG MARLA J				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) UNIVERSITY OF KENTUCKY LEXINGTON			8. PERFORMING ORGANIZATION REPORT NUMBER CI02-513	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) THE DEPARTMENT OF THE AIR FORCE AFIT/CIA, BLDG 125 2950 P STREET WPAFB OH 45433			10. SPONSORING/MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION AVAILABILITY STATEMENT Unlimited distribution In Accordance With AFI 35-205/AFIT Sup 1			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 words)				
20021029 033				
14. SUBJECT TERMS			15. NUMBER OF PAGES 11	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT	18. SECURITY CLASSIFICATION OF THIS PAGE	19. SECURITY CLASSIFICATION OF ABSTRACT	20. LIMITATION OF ABSTRACT	

Atherogenesis 2002

New Concepts In Plaque Vulnerability and C Reactive Protein

Marla J. De Jong, RN, MS,
CCNS, CCRN, CEN, Major

Objectives

- Discuss history of traditional thoughts on atherogenesis and how they have changed
- Discuss basic science of atherogenesis
- Discuss concept of plaque vulnerability
- Discuss concept of inflammation and C-reactive protein and fibrinogen in atherogenesis

Atherogenesis – Past and Present

History of Atherogenesis

- Inevitable degenerative process
- Lipid storage disease
- Arteries viewed as inanimate tubes
- Plaque rupture
- Occlusive thrombus

Atherogenesis Today

- Inflammatory process
- Endothelial dysfunction
- Neurohormonal factors
- Vessel narrowing vs. dilation

Process of Atherogenesis

Arterial Anatomy

- Intimal layer
- Medial layer
- Adventitial layer




Figure: Cotran et al. 1999. Robbins Pathologic Basis of Disease, 6th ed., Saunders

Lesion Initiation

- Endothelial damage
- Adhesion and chemoattractant molecules
 - Inflammatory leukocytes recruited
 - Extracellular lipid accumulates
- Fatty streaks




Figure: The Internet Pathology Laboratory for Medical Education

Fibrofatty stage

- Monocytes become macrophages
- Macrophages express scavenger receptors
- Macrophages ingest oxidized lipoproteins
- Lipid-laden foam cells arise




Figure: D. J. Simon
TCTMD.com

Extracellular Lipid Pools

- Foam cell necrosis
- Small lipid pools
- Smooth muscle cell proliferation/migration
- Compensatory vessel wall dilation





Figure: Vamvakis, AM; 2002. Circulation 105(8)

Glagov's Coronary Remodeling Concept



Glagov et al. N Engl J Med 1987;316:1375-1379

Core of Extracellular Lipid

- Lipid core forms
- Lesion expands
- Necrotic fatty core develops
- Fibrosis
- Effects of inflammatory mediators



Figure: Davies, MJ. 1996. Circulation 94(8)

Lesion Progression

- Fibrous cap forms
- Lumen narrows
- Plaque may calcify






Figure: The Internet Pathology Laboratory for Medical Education

Metalloproteinases (MMPs)

- Source
- Actions
- Regulation

Fibrous Cap Rupture

- Coagulation factors contact lipid core
- Thrombosis on nonocclusive plaque



Figures by Mr. Henry Stiller



Figure by Mr. Henry Stiller

Endothelial Erosion

- Intimal erosion
- Blood & platelets exposed to subendothelial matrix
- Proteinases are expressed
- Mural thrombus





Figure by Mr. Henry Stiller

Plaque Healing

- Fibrinolysis
- Smooth muscle cell proliferation
- Increase in plaque size

Arteries at Risk

- Shape of arteries
- Areas with preexisting intimal thickening



Plaque Vulnerability

Plaque Vulnerability Defined

- Asymptomatic atherosclerotic lesions with a tendency to rupture
- High risk for luminal thrombosis




Figure: The Internet Pathology Laboratory for Medical Education

Characteristics of Stable Lesions

- Many smooth muscle cells
- Thick fibrotic caps
- Limited amount of lipid
- A small, noninflamed lipid core

Characteristics of Unstable Lesions

- Mechanical factors
 - Vasospasm
 - Turbulent blood flow
 - Large liquid lipid core
 - Plaque flexion
 - Thin fibrous cap

Liao, JK; 1998

Characteristics of Unstable Lesions

- Fibrous cap
 - Decreased collagen synthesis
 - Collagen degradation
 - Smooth muscle cell loss
 - Increased cytokines

Liao, JK; 1998

Characteristics of Unstable Lesions

- Plaque constituents
 - Increased esterified cholesterol
 - Decreased extracellular matrix
 - Increased metalloproteinases
 - Increased T cells and macrophages
 - Warmer plaque temperature

Liao, JK; 1998

Other Triggers of Plaque Disruption

- Circadian variation
- Seasonal variation
- Physical exertion
- Emotional stress

Doering, LV; 1999

Inflammation and Atherogenesis

Triggers for Inflammation

- Oxidized lipoproteins
- Dyslipidemia
- Hypertension
- Diabetes
- Obesity
- Infection

Libby, P et al., 2002

Consequences of Inflammation

- Endothelial inflammation
- Leukocyte recruitment & adhesion
- Local inflammatory response
- Atheroma thrombotic complications
- Acute coronary syndromes

Markers of Inflammation

C-Reactive Protein (CRP)

C-Reactive Protein

- Acute-phase marker
- Easily measured
- hs-CRP
- Levels > 2 µg/ml indicate high risk
- Significance

Functions of CRP

- Induces expression of adhesion molecules
- Mediates LDL uptake
- Induces monocyte recruitment into artery wall
- Enhances production of MCP-1

Research Related to CRP

- CARE Trial
- Physician's Health Study
- Women's Health Study
- PRINCE Trial
- AFCAPS/TexCAPS Study

Other Inflammatory Markers

Fibrinogen

- Major coagulation factor
- Acute phase reactant
- Increases during inflammation
- May promote smooth muscle cell growth
- May attract WBCs
- May promote platelet aggregation
- May inhibit fibrinolysis

Interleukin 6

- Cytokine
- Affects platelet production
- Induces synthesis of acute phase proteins
- Predictor for CAD
- Levels > 5 ng/L → increased mortality

Myeloperoxidase (MPO)

- A leukocyte enzyme
- Promotes oxidation of lipoproteins
- May activate latent MMPs
- May cause plaque destabilization
- May cause endothelial dysfunction
- Levels correlate with CAD

Cellular Adhesion Molecules

- Selectins
- B2 integrins
- Immunoglobins

B-Type Natriuretic Peptide

- Reflects neurohormonal activity
- Prognostic marker for ACS & CHF
- Increases with transient ischemia
- Threshold level 80 pg/mL

Pregnancy-Associated Plasma Protein A (PAPP-A)

- A potentially proatherosclerotic MMP
- Present in unstable plaques
- Levels > 10 mIU associated with ACS
- Higher in pts with USA/AMI than in controls

Diagnostic Tools for Inflammation

- Angioscopy
- Thermal imaging
- Lasers
- High resolution IVUS
- Light-tipped catheters
- MRI
- Raman spectroscopy
- Magnetic resonance coronary angiography
- Electron beam computed tomography
- PET scanning
- Optical coherence tomography
- Intravascular shear stress imaging
- Microbubble contrast echocardiographic imaging
- Many others


Is There Any Hope?

Risk Factors for Atherosclerosis

- Smoking
- Hypertension
- Hypercholesterolemia
- Infections
- Diabetes
- Hypoxia
- Oxidants
- Turbulent Flow



Risk Reduction



- Cholesterol reduction
- ACE inhibitors
- Clopidogrel
- Aspirin
- Glucose control
- Smoking cessation
- Exercise

Unanswered Questions

- Do measurements of inflammation identify pts at risk, and do these independently predict risk beyond currently used tools?
- Are specific therapies available to reduce serum levels of markers of inflammation?
- Do therapies that lower serum levels of inflammatory markers reduce CV risk?
- Which is the optimal test for prognostic evaluation?
- Which pt population should be targeted for testing?
- What is the role of endothelial dysfunction compared to other new risk assessment strategies?

References

1. Albert CM, Ma J, Rifai N, Stampfer MJ, Ridker PM: Prospective study of C-reactive protein, homocysteine, and plasma lipid levels as predictors of sudden cardiac death. *Circulation*. 2002; 105(22): 2595-9.
2. Albert MA, Danielson E, Rifai N, Ridker PM, Investigators P: Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. *JAMA*. 2001; 286(1): 64-70.
3. Ambrose JA, Martinez EE: A new paradigm for plaque stabilization. *Circulation*. 2002; 105(16): 2000-4.
4. Bayes-Genis A, Conover CA, Overgaard MT, et al.: Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. *New England Journal of Medicine*. 2001; 345(14): 1022-9.
5. Buffon A, Biasucci LM, Liuzzo G, D'Onofrio G, Crea F, Maseri A: Widespread coronary inflammation in unstable angina. *New England Journal of Medicine*. 2002; 347(1): 5-12.
6. Burke AP, Kolodgie FD, Farb A, et al.: Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. *Circulation*. 2001; 103(7): 934-40.
7. Burke APMD, Kolodgie FDP, Farb AMD, Weber DBS, Virmani RMD: Morphological Predictors of Arterial Remodeling in Coronary Atherosclerosis. [Report]. *Circulation* January 22 2002; 105(3): 297-303.
8. de Lemos JA, Morrow DA, Bentley JH, et al.: The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. *New England Journal of Medicine*. 2001; 345(14): 1014-21.
9. Doering LV: Pathophysiology of acute coronary syndromes leading to acute myocardial infarction. *Journal of Cardiovascular Nursing*. 1999; 13(3): 1-20; quiz 119.
10. Fayad ZA, Fuster V: Clinical imaging of the high-risk or vulnerable atherosclerotic plaque. *Circulation Research*. 2001; 89(4): 305-16.
11. Feldman CL, Stone PH: Intravascular hemodynamic factors responsible for progression of coronary atherosclerosis and development of vulnerable plaque. *Current Opinion in Cardiology*. 2000; 15(6): 430-40.
12. Futterman LG, Lemberg L: Inflammation in plaque rupture: an active participant or an invited guest? *American Journal of Critical Care*. 1998; 7(2): 153-61.
13. Galis ZS, Khatri JJ: Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. *Circulation Research*. 2002; 90(3): 251-62.
14. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ: Compensatory enlargement of human atherosclerotic coronary arteries. *New England Journal of Medicine*. 1987; 316(22): 1371-5.
15. Heilbronn LK, Noakes M, Clifton PM: Energy restriction and weight loss on very-low-fat diets reduce C-reactive protein concentrations in obese, healthy women. *Arteriosclerosis, Thrombosis & Vascular Biology*. 2001; 21(6): 968-70.
16. Huang H, Virmani R, Younis H, Burke AP, Kamm RD, Lee RT: The impact of calcification on the biomechanical stability of atherosclerotic plaques. *Circulation*. 2001; 103(8): 1051-6.
17. Kennon S, Price CP, Mills PG, et al.: The effect of aspirin on C-reactive protein as a marker of risk in unstable angina. *Journal of the American College of Cardiology*. 2001; 37(5): 1266-70.

18. Kolodgie FD, Burke AP, Farb A, et al.: The thin-cap fibroatheroma: a type of vulnerable plaque: the major precursor lesion to acute coronary syndromes. *Current Opinion in Cardiology*. 2001; 16(5): 285-92.
19. Kullo IJ, Edwards WD, Schwartz RS: Vulnerable plaque: pathobiology and clinical implications. *Annals of Internal Medicine*. 1998; 129(12): 1050-60.
20. Liao JK: Endothelium and acute coronary syndromes. *Clinical Chemistry*. 1998; 44(8 Pt 2): 1799-808.
21. Libby P: Current concepts of the pathogenesis of the acute coronary syndromes. *Circulation*. 2001; 104(3): 365-72.
22. Libby P: The vascular biology of atherosclerosis. In: Braunwald E, Zipes DP, Libby P, eds. *Heart Disease: A Textbook of Cardiovascular Medicine*, 6th ed. Philadelphia: W.B. Saunders, 2001.
23. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. *Circulation*. 2002; 105(9): 1135-43.
24. Lindmark E, Diderholm E, Wallentin L, Siegbahn A: Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. *JAMA*. 2001; 286(17): 2107-13.
25. Pasceri V, Willerson JT, Yeh ET: Direct proinflammatory effect of C-reactive protein on human endothelial cells. *Circulation*. 2000; 102(18): 2165-8.
26. Pearson TA: New tools for coronary risk assessment: what are their advantages and limitations? *Circulation*. 2002; 105(7): 886-92.
27. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. *New England Journal of Medicine*. 1997; 336(14): 973-9.
28. Ridker PM, Hennekens CH, Buring JE, Rifai N: C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. *New England Journal of Medicine*. 2000; 342(12): 836-43.
29. Ridker PM, Rifai N, Clearfield M, et al.: Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. *New England Journal of Medicine*. 2001; 344(26): 1959-65.
30. Ridker PM, Genest J, Libby P: Risk factors for atherosclerotic disease. In: Braunwald E, Zipes DP, Libby P, eds. *Heart Disease: A Textbook of Cardiovascular Medicine*, 6th ed. Philadelphia: W.B. Saunders, 2001.
31. Schoenhagen P, McErlean ES, Nissen SE: The vulnerable coronary plaque. *Journal of Cardiovascular Nursing*. 2000; 15(1): 1-12.
32. Stefanadis C, Toutouzas K, Tsiamis E, et al.: Increased local temperature in human coronary atherosclerotic plaques: an independent predictor of clinical outcome in patients undergoing a percutaneous coronary intervention. *Journal of the American College of Cardiology*. 2001; 37(5): 1277-83.
33. Tchernof A, Nolan A, Sites CK, Ades PA, Poehlman ET: Weight loss reduces C-reactive protein levels in obese postmenopausal women. *Circulation*. 2002; 105(5): 564-9.
34. Tracy RP: Inflammation markers and coronary heart disease. *Current Opinion in Lipidology*. 1999; 10(5): 435-41.
35. Varnava AM, Mills PG, Davies MJ: Relationship between coronary artery remodeling and plaque vulnerability. *Circulation*. 2002; 105(8): 939-43.

36. Verma S, Anderson TJ: Fundamentals of endothelial function for the clinical cardiologist. *Circulation*. 2002; 105(5): 546-9.

37. Vorchheimer DA, Fuster V: Inflammatory markers in coronary artery disease: let prevention douse the flames. *JAMA*. 2001; 286(17): 2154-6.

38. Zhang R, Brennan ML, Fu X, et al.: Association between myeloperoxidase levels and risk of coronary artery disease. *JAMA*. 2001; 286(17): 2136-42.